Johnson & Johnson CEO Joaquin Duato says the company has no plans to enter the obesity market, instead focusing on areas such as cancer. He says oncology remains one of J&J's core growth pillars, and highlights dementia as another major challenge for the healthcare industry. Duato also talked about how artificial intelligence could accelerate drug discovery and the development of new medicines. He's on this week's episode of The David Rubenstein Show: Peer to Peer Conversations. This interview was recorded June 16 at The Economic Club of Washington.See omnystudio.com/listener for privacy information.